No major changes in RAAS-activity in the plasma of COVID-19 patients per se were found so far, but in COVID-19 patients treated with RAASi on the other hand, an increased plasma ACE2 activity could be observed, which was not observed in non-COVID-19 patients treated with RAASi [31,32,33]. This evidence concerns the gene ACE2 and COVID-19.